CO2020013679A2 - Formulaciones farmacéuticas mejoradas - Google Patents

Formulaciones farmacéuticas mejoradas

Info

Publication number
CO2020013679A2
CO2020013679A2 CONC2020/0013679A CO2020013679A CO2020013679A2 CO 2020013679 A2 CO2020013679 A2 CO 2020013679A2 CO 2020013679 A CO2020013679 A CO 2020013679A CO 2020013679 A2 CO2020013679 A2 CO 2020013679A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical formulations
formulation
improved pharmaceutical
combination
sorbitol
Prior art date
Application number
CONC2020/0013679A
Other languages
English (en)
Inventor
Ganeshchandra Sonavane
Parag Lokhande
Pradeep Sethi
Tushar Wagh
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CO2020013679A2 publication Critical patent/CO2020013679A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1664Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

RESUMEN La presente invención proporciona una formulación farmacéutica sólida fluida que comprende uno o más principios activos y una combinación que comprende sorbitol y parafina líquida, un envase que contiene la formulación, un procedimiento para la fabricación de la formulación y el uso de la combinación en la formulación.
CONC2020/0013679A 2018-05-02 2020-10-30 Formulaciones farmacéuticas mejoradas CO2020013679A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201811016594 2018-05-02
PCT/EP2019/060605 WO2019211159A1 (en) 2018-05-02 2019-04-25 Improved pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CO2020013679A2 true CO2020013679A2 (es) 2021-03-19

Family

ID=66290450

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0013679A CO2020013679A2 (es) 2018-05-02 2020-10-30 Formulaciones farmacéuticas mejoradas

Country Status (14)

Country Link
US (2) US11648201B2 (es)
EP (1) EP3787596A1 (es)
JP (1) JP2021522299A (es)
KR (1) KR20210005224A (es)
CN (1) CN112040929A (es)
BR (1) BR112020021852A2 (es)
CA (1) CA3099055A1 (es)
CL (1) CL2020002766A1 (es)
CO (1) CO2020013679A2 (es)
MX (2) MX2020011541A (es)
PH (1) PH12020551798A1 (es)
SG (1) SG11202010792TA (es)
TW (1) TW202002953A (es)
WO (1) WO2019211159A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021268903A1 (en) * 2020-05-08 2022-11-17 Fertin Pharma A/S Oral powder mixture with small sized particles

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2716624B1 (fr) * 1994-02-25 1996-05-03 Jouveinal Lab Gelée laxative hypocalorique à base d'huile de paraffine liquide et de lactulose, son procédé de préparation.
ITFI970184A1 (it) 1997-07-30 1999-01-30 Menarini Farma Ind Composizioni farmaceutiche contenenti vitamina d e calcio,loro preparazione ed uso terapeutico
RU2175554C2 (ru) 1999-03-30 2001-11-10 Пермское научно-производственное объединение "Биомед" Оральный препарат интерферона в виде таблеток
CZ300615B6 (cs) * 1999-11-30 2009-07-01 Panacea Biotec Limited Rychle rozpustný farmaceutický prostredek v pevné dávkové forme s prodlouženou sladkou chutí a zpusob jeho prípravy
WO2006020534A2 (en) * 2004-08-09 2006-02-23 Dr. Reddy's Laboratories Ltd. Stabilized desloratadine composition
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
AU2006226887A1 (en) * 2005-03-23 2006-09-28 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations
US7611739B2 (en) * 2006-01-06 2009-11-03 Amerilab Technologies, Inc. Method of using guava extract and composition including guava extract
US20090004270A1 (en) * 2006-01-06 2009-01-01 Amerilab Technologies, Inc. Method of using guava extract
EP1970053A1 (en) 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
US20100310668A1 (en) * 2008-02-13 2010-12-09 Ratiopharm Gmbh Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
EP2262534B1 (en) * 2008-03-10 2014-07-16 Bayer Consumer Care AG Palatable solid composition comprising antacid and saliva stimulant
WO2009120885A2 (en) * 2008-03-26 2009-10-01 Taro Pharmaceuticals U.S.A., Inc. Stabilizing lipid compositions for oral pharmaceutical agents
TR200806298A2 (tr) 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Farmasötik formülasyon
RU2454221C2 (ru) 2010-07-06 2012-06-27 Общество с ограниченной ответственностью "Завод Медсинтез" Способ получения лиофилизированного противовирусного средства
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
AR084865A1 (es) 2011-01-17 2013-07-10 Takeda Pharmaceutical Preparacion de desintegracion rapida, comprimido dispersable por via oral
WO2013077829A1 (en) * 2011-11-21 2013-05-30 Mahmut Bilgic Water-soluble pharmaceutical granules
MX2014013826A (es) * 2012-05-16 2018-04-24 Singh Mewa Composiciones farmaceuticas para la entrega de farmacos sustancialmente solubles en agua.
KR101814895B1 (ko) 2013-06-04 2018-01-04 바이옴 바이오사이언스 피브이티. 엘티디. 코팅된 입자 및 이를 포함하는 조성물

Also Published As

Publication number Publication date
EP3787596A1 (en) 2021-03-10
BR112020021852A2 (pt) 2021-02-23
US11648201B2 (en) 2023-05-16
TW202002953A (zh) 2020-01-16
WO2019211159A1 (en) 2019-11-07
US20230346704A1 (en) 2023-11-02
CA3099055A1 (en) 2019-11-07
MX2023008569A (es) 2023-08-08
CL2020002766A1 (es) 2021-02-19
MX2020011541A (es) 2020-11-24
US20210236426A1 (en) 2021-08-05
CN112040929A (zh) 2020-12-04
PH12020551798A1 (en) 2021-06-14
JP2021522299A (ja) 2021-08-30
KR20210005224A (ko) 2021-01-13
SG11202010792TA (en) 2020-11-27

Similar Documents

Publication Publication Date Title
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
SV2017005426A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
IL279034A (en) Pharmaceutical combination, composition and formulation containing a glucokinase activator and an alpha-glucosidase inhibitor, preparation methods and uses thereof
MX2020003661A (es) Formas de dosificacion de liquidos, metodos de fabricacion y uso.
SV2018005778A (es) Derivados aromaticos de sulfonamida
CL2021000741A1 (es) Composiciones plaguicidas sinérgicas y métodos para distribución de ingredientes activos insecticidas
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
AR104482A1 (es) Sistema de suministro de multi cámara
BR112016022340A2 (pt) Composição, uso cosmético de uma composição, medicamento e kit
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
UY36898A (es) Variantes de hppd y métodos de uso
CL2018001590A1 (es) Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina.
CL2018003418A1 (es) Formulaciones de óxido de polialquileno-asparaginasa y métodos de preparación y uso del mismo.
CO2020013679A2 (es) Formulaciones farmacéuticas mejoradas
SV2019005811A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
UY37261A (es) Formulación combinada de tres compuestos antivirales
CL2020000136A1 (es) Composiciones que contienen darunavir, cobicistat, emtricitabina y tenofovir alafenamida para uso en tratamiento de vih.
CL2018002577A1 (es) Forma física de un modulador sgr
AR107986A1 (es) Solubilización mejorada a través del uso de una combinación de surfactantes de cadena extendida
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
BR112018010616A2 (pt) compostos inibidores seletivos de mmp-12
EA201991594A1 (ru) Депо-препарат
CL2014001492A1 (es) Formulacion biocida capaz de impedir la proliferacion de microorgamismos en superficies
CL2015001970A1 (es) Una formulación liquida para el cuidado oral que comprende una mezcla de terpenos como principio activo
CL2019001944A1 (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla.